Sensei Biotherapeutics, Inc.
- Open
- 26.01
- Day high
- 26.99
- Day low
- 22.41
- Prev close
- 24.67
- Volume
- 146K
- Mkt cap
- $19M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 0.1
- P/S
- -3.8
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$364K over the last 3 months (26 open-market buys, 29 sales)
- 🏛Institutions accumulating (13F)
Sensei Biotherapeutics, Inc. (SNSE) is a Healthcare company listed on NASDAQ. The stock is up 171% over the past year. Over the trailing 3 months, insiders filed 26 open-market buys and 29 sales (SEC Form 4).
Sensei Biotherapeutics, Inc. (SNSE) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 4 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
SNSE earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 15, 2026 | $-0.62 | $-131.45 | -21101.6% | — | — |
| Mar 30, 2026 | $-4.81 | $-3.74 | +22.2% | — | — |
| Nov 14, 2025 | $-4.11 | $-3.62 | +11.9% | $-5M | — |
| Mar 28, 2025 | $-5.40 | $-5.40 | +0.0% | — | — |
| Nov 14, 2024 | $-6.20 | $-5.80 | +6.5% | — | — |
| May 9, 2024 | $-5.80 | $-6.40 | -10.3% | — | — |
| Feb 28, 2024 | $-6.40 | $-6.00 | +6.3% | — | — |
| Aug 3, 2023 | $-6.40 | $-6.20 | +3.1% | — | — |
| Mar 23, 2023 | $-0.40 | $-0.40 | +0.5% | — | — |
| Aug 9, 2022 | $-8.00 | $-6.80 | +15.0% | — | — |
| Mar 10, 2022 | $-6.80 | $-5.80 | +14.7% | — | — |
| Aug 4, 2021 | $-6.00 | $-6.40 | -6.7% | — | — |
SNSE insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 12, 2026 | Gerry Christopherofficer: President & PEO | Grant | 220,000 | $29.89 |
| Jun 12, 2026 | Donenberg Phillip B.director | Grant | 12,500 | $11.41 |
| Jun 12, 2026 | Holmen Bobdirector | Grant | 12,500 | $11.41 |
| Jun 1, 2026 | Cambrian BioPharma Inc10 percent owner | Sell | 476 | $21.14 |
| Jun 1, 2026 | Cambrian BioPharma Inc10 percent owner | Sell | 24,524 | $20.00 |
| Jun 1, 2026 | Peyer James10 percent owner, other: See remarks below | Sell | 24,524 | $20.00 |
| Jun 1, 2026 | Peyer James10 percent owner, other: See remarks below | Sell | 476 | $21.14 |
| May 15, 2026 | MILLENNIUM MANAGEMENT LLC10 percent owner | Sell | 374 | $33.35 |
| May 15, 2026 | MILLENNIUM MANAGEMENT LLC10 percent owner | Sell | 1,265 | $31.75 |
| May 15, 2026 | MILLENNIUM MANAGEMENT LLC10 percent owner | Sell | 3,099 | $30.86 |
| May 15, 2026 | MILLENNIUM MANAGEMENT LLC10 percent owner | Buy | 701 | $35.55 |
| May 15, 2026 | MILLENNIUM MANAGEMENT LLC10 percent owner | Buy | 1,276 | $34.75 |
| May 15, 2026 | MILLENNIUM MANAGEMENT LLC10 percent owner | Buy | 26 | $33.47 |
| May 15, 2026 | MILLENNIUM MANAGEMENT LLC10 percent owner | Buy | 4,995 | $25.99 |
| May 15, 2026 | MILLENNIUM MANAGEMENT LLC10 percent owner | Buy | 2,992 | $25.08 |
Source: SNSE SEC Form 4 filings, latest Jun 12, 2026. For informational purposes only — not investment advice.
See the full SNSE insider & 13F page →Sensei Biotherapeutics, Inc. company profile
Overview
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) is a clinical-stage biopharmaceutical company founded in 1999 and headquartered in Rockville, Maryland. Originally incorporated as Panacea Pharmaceuticals, Inc., the company went public in February 2021 and focuses on developing innovative immunotherapies for cancer treatment. The company operates two proprietary technology platforms designed to harness the body's immune system to fight cancer, representing a next-generation approach to oncology treatment.
Business
Sensei Biotherapeutics operates in the biotechnology sector, specifically focusing on immuno-oncology - a field that develops treatments to help the patient's immune system recognize and destroy cancer cells more effectively. Traditional cancer treatments like chemotherapy directly attack cancer cells but often damage healthy cells in the process. Immunotherapy, by contrast, works by training or enhancing the patient's own immune system to better identify and eliminate cancer cells while leaving healthy tissue largely unharmed. The company develops treatments through two main technology platforms. The first is the ImmunoPhage platform, which uses bacteriophages (viruses that naturally infect bacteria) as delivery vehicles to present cancer-associated antigens to the immune system. This approach is designed to trigger both innate and adaptive immune responses against tumors. The second platform focuses on Tumor Microenvironment Activated Biologics, which develops antibodies that become active specifically within the tumor environment, targeting immune checkpoints and other critical immune pathways to unleash T-cell activity against cancer. The company's lead product candidates include SNS-101, a monoclonal antibody for cancer treatment, and SNS-401-NG, an ImmunoPhage-based vaccine that targets multiple tumor antigens. Sensei also maintains a research collaboration with The University of Washington specifically focused on developing a vaccine for Merkel cell carcinoma, a rare but aggressive form of skin cancer.
Revenue model
As a clinical-stage biopharmaceutical company, Sensei Biotherapeutics currently generates no revenue from product sales, as its treatments are still in development and have not yet received regulatory approval for commercial use. The company operates on a typical biotech business model where it funds research and development activities through equity financing, grants, and potential future partnerships or licensing deals. The company's future revenue potential will depend on successfully advancing its product candidates through clinical trials, obtaining regulatory approval from agencies like the FDA, and then either commercializing the treatments directly or partnering with larger pharmaceutical companies for distribution. Revenue could eventually come from direct product sales, licensing fees, milestone payments from partners, or royalties on sales. Several factors could significantly impact the company's financial performance and margins. Positive clinical trial results would likely increase the company's valuation and ability to secure additional funding or partnerships, while negative results could severely impact its prospects. The competitive landscape in immuno-oncology is intense, with major pharmaceutical companies and numerous biotechs developing similar approaches. Regulatory changes, healthcare reimbursement policies, and the overall appetite for biotech investments also significantly influence the company's ability to fund operations and advance its programs. Additionally, the company's burn rate and ability to manage cash resources efficiently will determine how long it can continue operations without additional financing.
Competitive moat
Sensei Biotherapeutics operates in a highly competitive field with limited sustainable competitive advantages typical of early-stage biotechnology companies. The company's primary potential moat lies in its proprietary ImmunoPhage platform, which represents a relatively novel approach to cancer immunotherapy using bacteriophages as delivery vehicles. This technology could provide differentiation if proven effective in clinical trials, as it combines the specificity of targeted therapy with the broad immune activation potential of vaccines. However, the company's moat is currently weak and largely theoretical. The biotechnology industry is characterized by rapid innovation, significant patent competition, and the constant threat of larger pharmaceutical companies developing superior approaches with greater resources. Major players like Bristol Myers Squibb, Merck, and Roche have substantial immuno-oncology portfolios and can quickly adapt or acquire promising technologies. Additionally, the regulatory approval process creates substantial execution risk - even promising early-stage results may not translate to successful commercial products. The company's small size and limited financial resources also constrain its ability to compete effectively. Unlike established pharmaceutical companies with diversified product portfolios, Sensei faces an all-or-nothing scenario where failure of its lead programs could effectively end the business. The competitive threat comes not only from direct competitors developing similar immunotherapy approaches but also from entirely different treatment modalities that could prove more effective or easier to develop and commercialize.
Risks & safety
The margin of safety appears limited given the company's current financial position and inherent biotech risks. • Cash position and burn rate: With approximately $9.9 million in cash and short-term investments as of Q1 2025, and quarterly cash burn of roughly $7 million, the company has less than two quarters of operating runway without additional financing • Debt levels: Low debt-to-equity ratio of 0.10, indicating minimal leverage risk • Solvency risk: High near-term financing risk given rapid cash depletion and no revenue generation • Current ratio: Strong at 6.8, indicating good short-term liquidity relative to current liabilities • Valuation metrics: Trading at 0.31x book value and negative earnings multiples due to losses, suggesting potential asset value but high execution risk • Market cap: Extremely small at under $9 million, indicating high volatility and limited institutional interest • Graham net-net: Ratio above 1.0 suggests trading below liquidation value, providing some downside protection
Recent development
Based on the available financial data, Sensei Biotherapeutics has been consistently advancing its research and development programs while managing a controlled cash burn rate. Over the past few years, the company has maintained focus on its two core technology platforms - the ImmunoPhage approach and Tumor Microenvironment Activated Biologics. The company's quarterly cash burn has remained relatively stable at around $5-7 million per quarter, suggesting disciplined expense management while continuing to fund clinical development activities. The balance sheet shows the company has been managing its cash resources carefully, though the declining cash position from over $19 million in Q3 2024 to under $10 million in Q1 2025 indicates accelerated spending or milestone-driven activities. The collaboration with The University of Washington for Merkel cell carcinoma vaccine development represents a strategic partnership approach that allows the company to advance additional programs without bearing the full development costs internally. This partnership model could be indicative of the company's strategy to leverage external collaborations to expand its pipeline while preserving cash resources for its core proprietary programs.
SNSE company profile · for informational purposes only — not investment advice.
Track SNSE with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free